1. Barnes PJ, Karin M: Nuclear factor-kappaB: A piv- otal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
  2. Benbow U, Brinckerhoff CE: The AP-1 site and MMP gene regulation: What is all the fuss about? Matrix Biol 1997;15:519-526.
  3. Crawford HC, Matrisian LM: Mechanisms control- ling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 1996;49:20-37.
  4. He C: Molecular mechanism of transcriptional acti- vation of human gelatinase B by proximal pro- moter. Cancer Lett 1996;106:185-191.
  5. Delves PJ, Roitt IM: The immune system: First of two parts. N Engl J Med 2000;343:37-49.
  6. Anderson GR, Volpe CM, Russo CA, et al: The anoxic fibroblast response is an early-stage wound healing program. J Surg Res 1995;59:666-674.
  7. Andersson EC, Hansen BE, Jacobsen H, et al: Defi- nition of MHC and T cell receptor contacts in the HLA-DR4 restricted immunodominant epitope
    in type II collagen and characterization of collagen- induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc Natl Acad Sci USA 1998;95:7574-7579.
  8. Shoenfeld Y, Alarcon-Segovia D, Buskila M, et al: Frontiers of SLE: Review of the 5th International Congress of Systemic Lupus Erythematosus, Can- cun, Mexico, April 20-25, 1998. Semin Arthritis Rheum 1999;29:112-130.
  9. Maddison PJ: Autoantibodies in SLE: Disease asso- ciations. Adv Exp Med Biol 1999;455:141-145.
  10. Agudelo CA, Wise CM: Gout: Diagnosis, patho- genesis, and clinical manifestations. Curr Opin Rheumatol 2001;13:234-239.

11. Delves PJ, Roitt IM: The immune system: Second of two parts. N Engl J Med 2000;343:108-117.

12. Burger D: Cell contact interactions in rheumatol- ogy, The Kennedy Institute for Rheumatology, London, UK, 1-2 June 2000. Arthritis Res 2000;2:472-476.

13. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916.

14. Gallagher G, Dickensheets H, Eskdale J, et al: Cloning, expression and initial characterization of interleukin-19 (IL- 19): A novel homologue of human interleukin-10 (IL-10). Genes Immun 2000;1:442-450.

15. Sunderkotter C, Steinbrink K, Goebeler M, et al: Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-422.

16. Yanagisawa K, Hamada K, Gotoh M, et al: Vascu- lar endothelial growth factor (VEGF) expression in the subacromial bursa is increased in patients with impingement syndrome. J Orthop Res 2001;19:448-455.

17. Stein CM, Pincus T: Glucocorticoids, in Kelley WN, Harris ED Jr, Ruddy S, Sledge CB (eds): Textbook of Rheumatology, ed 5. Philadelphia, PA, WB Saun- ders, 1997, pp 787-803.

18. Bresnihan B, Cunnane G, Youssef P, et al: Micro- scopic measurement of synovial membrane inflam- mation in rheumatoid arthritis: Proposals for the evaluation of tissue samples by quantitative analy- sis. Br J Rheumatol 1998;37:636-642.

19. Fassbender HG: What destroys the joint in rheu- matoid arthritis? Arch Orthop Trauma Surg 1998;117:2-7.

20. Feldmann M, Charles P, Taylor P, et al: Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol 1998;20:211-228.

21. Ohshima S, Saeki Y, Mima T, et al: Long-term follow-up of the changes in circulating cytok- ines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol 1999;19:305-313.

22. Evans CH, Robbins PD, Ghivizzani SC, et al: Abstract: Results from the first human clinical trial of gene therapy for arthritis. Arthritis Rheum 1999;42(suppl 9):S170.